Volume 44, Number 5
September 2014
Letter From the Editors he predominant application of PET is in the field of oncology. However, we should not forget that cardiac studies were the earliest approved PET techniques and that they have made an ever-increasing impact in clinical medicine since that time. Clearly, 18F-FDG, the primary PET agent, has a role in myocardial viability, and it has also been used increasingly in the diagnosis of cardiac sarcoidosis.1 Dr Travin points out in his guest editorial that quantitative coronary blood flow measurements are now possible with perfusion agents such as 82Rb and 13NH3 as well as with 18FFlurpridaz, a promising new agent.2,3 This new technique, as it becomes more widely available, promises to greatly improve our diagnostic accuracy of coronary artery disease. This 2-part update on Cardiovascular Nuclear Medicine provides a very useful state-of-the-art review of this important aspect of our specialty. We thank our guest editor, Dr Mark
T
http://dx.doi.org/10.1053/j.semnuclmed.2014.07.001 0001-2998/& 2014 Elsevier Inc. All rights reserved.
Travin, who has assembled a fine group of authors to discuss this subject. Further perspective of the subject can be gained from reading Dr Travin's editorial and, in particular, the accompanying articles. Leonard M. Freeman, MD M. Donald Blaufox, MD, PhD
References 1. Jain D, He Z-X, Lele V: Cardiac hot spot imaging with 18FDG. Semin Nucl Med 2014;44(5):374-384 2. Travin MI: Letter From the guest editor: Update in cardiovascular nuclear medicine (part II). Semin Nucl Med 2014;44(5):332 3. Dorbala S, Di Carli F: Cardiac PET perfusion: Prognosis, risk stratification, and clinical management. Semin Nucl Med 2014;44(5):344-357
331
September 2014
Letter From the Editors he predominant application of PET is in the field of oncology. However, we should not forget that cardiac studies were the earliest approved PET techniques and that they have made an ever-increasing impact in clinical medicine since that time. Clearly, 18F-FDG, the primary PET agent, has a role in myocardial viability, and it has also been used increasingly in the diagnosis of cardiac sarcoidosis.1 Dr Travin points out in his guest editorial that quantitative coronary blood flow measurements are now possible with perfusion agents such as 82Rb and 13NH3 as well as with 18FFlurpridaz, a promising new agent.2,3 This new technique, as it becomes more widely available, promises to greatly improve our diagnostic accuracy of coronary artery disease. This 2-part update on Cardiovascular Nuclear Medicine provides a very useful state-of-the-art review of this important aspect of our specialty. We thank our guest editor, Dr Mark
T
http://dx.doi.org/10.1053/j.semnuclmed.2014.07.001 0001-2998/& 2014 Elsevier Inc. All rights reserved.
Travin, who has assembled a fine group of authors to discuss this subject. Further perspective of the subject can be gained from reading Dr Travin's editorial and, in particular, the accompanying articles. Leonard M. Freeman, MD M. Donald Blaufox, MD, PhD
References 1. Jain D, He Z-X, Lele V: Cardiac hot spot imaging with 18FDG. Semin Nucl Med 2014;44(5):374-384 2. Travin MI: Letter From the guest editor: Update in cardiovascular nuclear medicine (part II). Semin Nucl Med 2014;44(5):332 3. Dorbala S, Di Carli F: Cardiac PET perfusion: Prognosis, risk stratification, and clinical management. Semin Nucl Med 2014;44(5):344-357
331
